Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

indium In 111 tabituximab barzuxetan

A radioconjugate consisting of tabituximab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against Frizzled-10 (FZD10; CD350), conjugated to the diethylenetriaminepentaacetic acid (DTPA) chelator derivative barzuxetan and labeled with the gamma-emitting isotope indium In 111, which may be used to detect FZD10-expressing tumor cells upon gamma scintigraphy. Upon administration of indium In 111 tabituximab barzuxetan, tabituximab targets and binds to FZD10 expressed on tumor cells. This allows for visualization of FZD10-expressing tumor cells upon gamma scintigraphy. FZD10, a member of the Frizzled family of G protein-coupled receptors, is one of the components in the Wnt/beta-catenin signaling pathway that plays key roles in embryogenesis and cancer growth.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:111In tabituximab barzuxetan
indium In 111-labeled tabituximab barzuxetan
OTSA101-DTPA-111In
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search